ACAD
Price:
$16.37
Market Cap:
$2.72B
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for...[Read more]
Industry
Biotechnology
IPO Date
2004-05-27
Stock Exchange
NASDAQ
Ticker
ACAD
According to ACADIA Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 2.61B. This represents a change of -18.89% compared to the average of 3.22B of the last 4 quarters.
The mean historical Enterprise Value of ACADIA Pharmaceuticals Inc. over the last ten years is 4.06B. The current 2.61B Enterprise Value has changed 6.32% with respect to the historical average. Over the past ten years (40 quarters), ACAD's Enterprise Value was at its highest in in the December 2020 quarter at 8.23B. The Enterprise Value was at its lowest in in the June 2018 quarter at 1.83B.
Average
4.06B
Median
3.55B
Minimum
1.91B
Maximum
8.13B
Discovering the peaks and valleys of ACADIA Pharmaceuticals Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 219.75%
Maximum Annual Enterprise Value = 8.13B
Minimum Annual Increase = -55.04%
Minimum Annual Enterprise Value = 1.91B
Year | Enterprise Value | Change |
---|---|---|
2023 | 5.00B | 98.23% |
2022 | 2.52B | -31.01% |
2021 | 3.65B | -55.04% |
2020 | 8.13B | 32.97% |
2019 | 6.11B | 219.75% |
2018 | 1.91B | -47.21% |
2017 | 3.62B | 13.98% |
2016 | 3.18B | -8.83% |
2015 | 3.49B | 15.19% |
2014 | 3.03B | 42.03% |
The current Enterprise Value of ACADIA Pharmaceuticals Inc. (ACAD) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
3.72B
5-year avg
5.08B
10-year avg
4.06B
ACADIA Pharmaceuticals Inc.’s Enterprise Value is less than Madrigal Pharmaceuticals, Inc. (7.46B), less than Viking Therapeutics, Inc. (5.81B), less than Sarepta Therapeutics, Inc. (12.11B), greater than Hepion Pharmaceuticals, Inc. (5.35M), less than PTC Therapeutics, Inc. (3.21B), greater than Reviva Pharmaceuticals Holdings, Inc. (33.37M), greater than Athira Pharma, Inc. (-42716438.00), greater than Fortress Biotech, Inc. (57.12M), greater than Cabaletta Bio, Inc. (-63983636.00), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Terns Pharmaceuticals, Inc. (222.97M), greater than Akero Therapeutics, Inc. (2.00B), less than Reata Pharmaceuticals, Inc. (6.64B), less than Krystal Biotech, Inc. (5.10B), less than Blueprint Medicines Corporation (6.36B),
Company | Enterprise Value | Market cap |
---|---|---|
7.46B | $7.58B | |
5.81B | $5.86B | |
12.11B | $10.91B | |
5.35M | $4.62M | |
3.21B | $3.33B | |
33.37M | $38.12M | |
-42716438.00 | $24.83M | |
57.12M | $44.44M | |
-63983636.00 | $91.40M | |
915.81M | $794.69M | |
222.97M | $491.80M | |
2.00B | $2.28B | |
6.64B | $6.57B | |
5.10B | $5.48B | |
6.36B | $5.98B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ACADIA Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ACADIA Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is ACADIA Pharmaceuticals Inc.'s Enterprise Value?
What is the highest Enterprise Value for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the 3-year average Enterprise Value for ACADIA Pharmaceuticals Inc. (ACAD)?
What is the 5-year average Enterprise Value for ACADIA Pharmaceuticals Inc. (ACAD)?
How does the current Enterprise Value for ACADIA Pharmaceuticals Inc. (ACAD) compare to its historical average?